Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group
- 341 Downloads
We aimed to describe the real-world efficacy and safety of combination therapy with ledipasvir and sofosbuvir (LDV/SOF) for chronic hepatitis C virus (HCV) genotype 1 (GT1) infection.
This retrospective analysis of a prospective, nationwide, multicenter registry included GT1-infected patients treated with LDV/SOF for 12 weeks. We assessed the rate of sustained virological response at 12 weeks post-treatment (SVR12), incidence of adverse events, and serum markers of hepatocellular carcinoma (HCC).
Among the 1461 patients included (mean age, 69 years; 29.5% aged > 75 years; cirrhosis, 23.8%; history of treatment for HCC, 10.9%), the overall SVR12 rate was 98.4% (1438/1461). Factors associated with treatment failure were cirrhosis (odds ratio, 4.19; p = 0.014) and resistance-associated substitutions (RASs) in NS5A at baseline (odds ratio, 7.78; p = 0.0004). The SVR12 rate in patients with cirrhosis and NS5A RASs was 93.0% compared to 100% in patients without cirrhosis or NS5A RASs. In patients with SVR, the levels of alpha-fetoprotein (AFP), AFP-L3, and Mac-2 binding protein glycosylation isomer (M2BPGi) decreased from baseline to end of treatment (from 13.4 ± 37.6 to 6.0 ± 10.6 ng/mL, p < 0.0001; from 2.2 ± 4.9 to 1.5 ± 6.3%, p < 0.005; and from 3.6 ± 3.7 to 2.0 ± 3.5 cut-off index, p < 0.0001; respectively). Adverse events were rare and not associated with age. No decrease in estimated glomerular filtration rate was observed in patients with baseline chronic kidney disease stage 3.
LDV/SOF therapy is highly effective and safe in elderly Japanese patients with HCV GT1, even in the presence of cirrhosis or NS5A RASs. Patients with SVR may have a lower risk of HCC.
KeywordsChronic hepatitis C Ledipasvir Sofosbuvir Alpha-fetoprotein
This study was supported by a Grant-in aid from the Japan Agency for Medical Research and Development (Grant number: 15fk0210007h0002).
- 4.American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 16 Sept 2016.
- 5.The Japan Society for Hepatology. JSH guidelines for management of hepatitis C virus infection (ver. 5.2). 2016. http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c. Accessed 15 Dec 2016.
- 7.Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA. 2002;99:15584–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomized, phase 3 trial. Lancet Infect Dis. 2015;15:645–53.CrossRefPubMedGoogle Scholar
- 15.Kanda T, Yasui S, Nakamura M, et al. Real- world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3/4A inhibitors. Int J Mol Sci. 2017;18:906.CrossRefPubMedCentralGoogle Scholar
- 28.Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015;10:e129053.Google Scholar